NOXAFIL® (posaconazole) is a triazole antifungal agent available as a suspension for oral administration.
NOXAFIL® (posaconazole) Oral Suspension is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. (See MICROBIOLOGY and CLINICAL STUDIES.)
Published Studies Related to Noxafil (Posaconazole)
Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin. [2011.01]
The objective of this phase 1, open-label, parallel, randomized study was to determine the effect of posaconazole on the pharmacokinetics of caspofungin and micafungin in 67 healthy subjects. Caspofungin (70 mg on day 1, 50 mg on days 2-14 once daily; 1-hour intravenous infusion) (cohort 1) or micafungin (150 mg once daily days 1-7; 1-hour IV infusion) (cohort 2) was administered alone or with posaconazole oral suspension 400 mg twice daily, on days 1 to 14 (cohort 1) or days 1 to 7 (cohort 2).
Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. [2010.09]
The objective of this study was to evaluate the cost-effectiveness of posaconazole versus fluconazole for the prevention of invasive fungal infections (IFI) in graft-versus-host disease (GVHD) patients in the Netherlands. A decision analytic model was developed based on a double-blind randomized trial that compared posaconazole with fluconazole antifungal prophylaxis in recipients of allogeneic HSCT with GVHD who were receiving immunosuppressive therapy (Ullmann et al., N Engl J Med 356:335-347, 2007)...
Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. [2010.07]
The purpose of this article is to report the exposure-response (E-R) relationship of posaconazole oral suspension (POS) for prophylaxis against invasive fungal infections (IFIs), on the basis of the US Food and Drug Administration (FDA) clinical pharmacology review of two randomized, active-controlled clinical studies...
[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome]. [2010.06]
The objective of this study was to assess the costs and effectiveness (avoided invasive fungal infections - IFIs; overall mortality) of prophylaxis with posaconazole 200 mg per os TID and standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID) in neutropenic patients with acute myelogenous leukaemia or myelodysplastic syndromes.
Skin concentrations and pharmacokinetics of posaconazole after oral administration. [2010.05]
A randomized, single-center, open-label study of posaconazole (POS) was performed to determine the concentration of POS in the skin of 30 healthy adult human subjects receiving 400 mg POS oral suspension twice daily for 8 days with a high-fat meal. Blood samples for plasma POS level determination were collected at prespecified times on day 1 and day 8...
Clinical Trials Related to Noxafil (Posaconazole)
A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) [Completed]
Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615) [Completed]
The purpose of this study is to collect pharmacokinetic (PK) information related to how well
posaconazole tablet is distributed in the body and to determine the safety of this new
formulation. The study consists of a Phase 1B study that includes participants with
neutropenia undergoing chemotherapy for acute myelogenous leukemia (AML) or myelodysplasia
(MDS) and a Phase 3 study that includes participants who are undergoing chemotherapy for AML
or MDS and participants who are recipients of allogeneic hematopoietic stem cell transplant
Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir [Completed]
The purpose of this study is to determine the influence of posaconazole on unboosted
fosamprenavir pharmacokinetics, and vice versa, in healthy volunteers. A second objective is
to determine the safety of combined use of fosamprenavir with posaconazole in healthy
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia [Completed]
The goal of this clinical research study is to learn the amount of posaconazole that is in
the body at different time points when given to patients with leukemia. The safety of this
drug will also be studied.
To study the plasma pharmacokinetics of posaconazole in patients with newly diagnosed acute
myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) undergoing
induction chemotherapy or relapsed or refractory patients who will receive salvage
To evaluate the safety of posaconazole given as prophylaxis.
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) [Completed]
The objective of this study is to compare the safety and efficacy of ABLC versus oral
Posaconazole in the prevention of invasive fungal infections in high risk patients with
hematologic malignancies or hematopoietic stem cell transplant.
Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal
infections associated with ABLC or Posaconazole prophylaxis.
Secondary objective will be to compare the cost effectiveness of these two prophylactic
Reports of Suspected Noxafil (Posaconazole) Side Effects
Drug Interaction (14),
Sinoatrial Block (7),
Atrioventricular Block Second Degree (6),
Nodal Arrhythmia (5),
Septic Shock (5),
Sinus Tachycardia (5),
Sinus Bradycardia (4),
Diabetes Mellitus (3),
Neuropathy Peripheral (3), more >>